- Conditions
- Eating Disorders, Hypoestrogenemia
- Interventions
- 17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 35 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obesity, Infertility
- Interventions
- Estradiol, Gonadotropin-releasing hormone (GnRH), Progesterone
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hot Flashes
- Interventions
- Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays, Placebo transdermal two 90 μL sprays, Placebo transdermal three 90 μL sprays, Placebo transdermal one 90 μL spray
- Drug
- Lead sponsor
- Lumara Health, Inc.
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Oro Valley, Arizona + 37 more
- Conditions
- Menopause
- Interventions
- Premarin® (oral) vs. Alora® (transdermal)
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 42 Years to 70 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Transdermal Estradiol
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 6
- States / cities
- Freehold, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 2 more
- Conditions
- Obesity
- Interventions
- leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Anorexia Nervosa
- Interventions
- RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 22 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mammographic Density, Abnormal Mammogram
- Interventions
- CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 517 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pregnancy Related, Cannabis Use
- Interventions
- Dronabinol
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 40 Years to 66 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Menopause, Postmenopause, Premenopause, Cardiovascular Disease
- Interventions
- transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 47 Years to 55 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2005
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Alzheimer Disease
- Interventions
- Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Suicidal Ideation
- Interventions
- Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Type 2, Dementia
- Interventions
- Estradiol patch
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years to 80 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Premature Ovarian Insufficiency
- Interventions
- Progesterone, Estrogen Patch
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 11 Years to 19 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Failure, Premature
- Interventions
- 17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Menopause, Healthy Female Participants
- Interventions
- Estradiol/Levonorgestrel Transdermal System
- Drug
- Lead sponsor
- Corium Innovations, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Cancer of the Prostate
- Interventions
- BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
- Drug
- Lead sponsor
- BHR Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
- Conditions
- Major Depressive Disorder
- Interventions
- Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Menopause, Obesity, Abdominal, Aging, Weight Gain
- Interventions
- GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Follicle Stimulating Hormone Glycosylation, Urinary FSH21/FSH24 Ratio, Estradiol Effect
- Interventions
- Estradiol Transdermal Product
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 20 Years to 55 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Turner's Syndrome
- Interventions
- Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 138 Months to 13 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan